Full-Time

Accounting Senior Manager

Updated on 5/26/2026

Kura Oncology

Kura Oncology

201-500 employees

Clinical-stage oncology company develops targeted therapies

Compensation Overview

$143k - $176.5k/yr

+ Bonus + Equity

San Diego, CA, USA

In Person

Category
Accounting
Required Skills
NetSuite
Coupa
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in accounting, or other related discipline, or the equivalent knowledge and experience required
  • Experience in the biotech/pharmaceutical industry required
  • A minimum of 6-8 years’ relevant accounting experience, preferably in a combination of the following monthly close process, bank reconciliations, balance sheet reconciliations, contract accruals
  • Knowledge of US Generally Accepted Accounting Principles and internal control principles for a public corporation
  • ERP experience required; experience with NetSuite, Blackline, Coupa and Concur preferred
  • Skilled in the use of Microsoft Office Suite with intermediate to advanced Excel skills
  • Excellent communication and people skills and the ability to interface with various levels of co-workers, upper management, and external customers while maintaining a high degree of confidentiality
  • Exercises independent judgment in managing operational decisions within their area; proactively identifies issues and determines when to escalate more complex or cross-functional decisions
  • Ability to work in a team environment and willing to assist other team members to achieve team goals and objectives
  • The base range for this role at a Senior Manager level is $143,000 - $176,500.
Responsibilities
  • Manage Senior Accountant and ensure timely, accurate processing of journal entries, reconciliations and various account analyses for R&D functions such as translational research, development, diagnostics, pharmacology, and regulatory affairs, and adherence to company policies
  • Review and approve invoices for payment. Ensure proper coding, two-way match, and approval workflows
  • Perform and review journal entries and balance sheet reconciliations for key accounts such as accrued R&D contracts, prepaid R&D Short-Term, and prepaid R&D Long-Term
  • Review various related parties and partner transactions including reconciliations, and analysis
  • Perform and review monthly and quarterly variance analyses for operating expenses, R&D functions, projects, and key accounts; investigate and resolve discrepancies proactively
  • Ensure compliance with U.S. GAAP, SOX requirements, and internal accounting policies across all responsible functions and processes
  • Support the design, implementation, and ongoing maintenance of Sarbanes‑Oxley internal controls, including documentation and testing
  • Assist with external financial audits by preparing schedules and responding to auditor requests and inquiries
  • Review monthly purchase order coding, partner with project managers and accounting staff to ensure proper coding for all new purchase orders
  • Apply strong analytical skills and critical thinking to identify issues, recommend improvements, and enhance the accuracy, efficiency, and quality of accounting processes
  • Perform additional duties and ad hoc projects as needed to support Finance leadership and departmental goals
Desired Qualifications
  • Experience working in publicly traded company and life science industry preferred
  • Kura’s values or culture alignment statements are not typically desirable qualifications for a role, so they are not included as desirable items

Kura Oncology develops precision medicines for cancer, focusing on small-molecule drugs that target tumors with specific genetic mutations. It is in the clinical-stage, researching and developing its own drug candidates to eventually bring them to market. Its leading candidate, ziftomenib, blocks the menin-KMT2A/MLL protein interaction, offering a targeted approach for genetically defined acute myeloid leukemia (AML). The company is also pursuing tipifarnib for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. By collaborating with academic institutions and other biotech companies, Kura Oncology expands its pipeline and advances therapies through clinical trials. The goal is to deliver effective, targeted cancer treatments for patients with unmet medical needs and to grow its portfolio through research, development, and partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Early KOMZIFTI sales and payer coverage show initial commercial traction.
  • Kyowa Kirin partnership delivered $165 million in milestones during 2025.
  • Cash and collaboration payments fund AML development through 2028 phase 3 readouts.

What critics are saying

  • Syndax already competes in menin-inhibitor AML, pressuring pricing and switching.
  • KOMET-017 failure would damage ziftomenib's frontline expansion and valuation.
  • Tipifarnib and KO-2806 consume capital without proven commercial success.

What makes Kura Oncology unique

  • KOMZIFTI is Kura's FDA-approved once-daily oral menin inhibitor for NPM1-mutated AML.
  • KOMET-017 tests both intensive and non-intensive frontline AML regimens globally.
  • Kura also advances tipifarnib and KO-2806 against solid-tumor resistance pathways.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Kura Oncology who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Paid Paternity/Maternity Leave

Home Office Stipend

Lifestyle Spending Stipend

Commuter Stipend

Wellness Program

Gym Membership

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

3%
Yahoo Finance
Mar 6th, 2026
Kura Oncology's Komzifti generates $2.1M in first weeks, triggers $135M milestone

Kura Oncology launched Komzifti, generating $2.1 million in net product revenue in late 2025. The company achieved rapid market access with payers covering most private and insured lives pre-approval, supported by an NCCN Category 2A listing and its KuraConnect programme. The company is advancing ziftomenib through the registrational KOMET-017 programme for earlier-stage AML treatment and developing multiple combinations with venetoclax and FLT3 inhibitors. Key data updates are expected in the first half of 2026. The first commercial sale triggered a $135 million milestone payment. Kura ended 2025 with $667.2 million in cash, which management says will fund the ziftomenib programme through anticipated phase 3 results, despite a fourth-quarter net loss of $81 million.

Yahoo Finance
Mar 5th, 2026
Kura Oncology's Comzifty generates $2.1M in first product revenue, triggers $135M milestone payment

Kura Oncology reported its first product revenue of $2.1 million from Comzifty in late 2025, marking its transition to a commercial-stage biopharmaceutical company. The company secured $135 million in milestone payments from Kyowa Kirin following the first commercial sale. Comzifty achieved 84% private payer coverage within 90 days of launch and received NCCN Category 2A recommendation within one week of submission. The company secured patent protection through July 2044. Management is pursuing a "first-to-frontline" strategy, targeting the $350 million to $400 million relapsed/refractory NPM1 market as an entry point to the broader $7 billion US AML opportunity. Pivotal COMET-017 frontline trial data readouts are expected to support potential accelerated FDA approvals, with current cash reserves funding operations through Phase 3 results in 2028.

Yahoo Finance
Mar 5th, 2026
Kura Oncology reports $667M cash position to support AML drug development to Phase 3

Kura Oncology has reported early commercial momentum for KOMZIFTI (ziftomenib), its once-daily oral menin inhibitor for relapsed or refractory acute myeloid leukaemia with NPM1 mutations. The drug generated $2.1 million in net revenue during the fourth quarter of 2025, based on approximately five weeks of sales following FDA approval on 13 November. The company achieved approximately 80% private payer coverage within 90 days of launch, with policies aligned to the label without additional restrictions. FDA Orange Book patent listings extend to 2044, supporting long-term market exclusivity. Kura reported $667.2 million in cash, cash equivalents and short-term investments, with an additional $180 million in anticipated collaboration payments, including a $135 million milestone from Kyowa Kirin. The company expects multiple clinical data milestones in 2026 across its AML and solid tumour programmes.

Stock Titan
Dec 2nd, 2025
Kura Oncology receives $135M milestone payment from Kyowa Kirin after first US sale of KOMZIFTI

Kura Oncology has received a $135 million milestone payment from Kyowa Kirin following the first US commercial sale of KOMZIFTI™. The payment was triggered under the companies' collaboration and licence agreement. The milestone represents a significant commercial achievement for the partnership between the two pharmaceutical companies. KOMZIFTI has now entered the US market, marking an important step in the drug's commercialisation.

GlobeNewswire
Oct 24th, 2025
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Kura Oncology receives $30 million development milestone payment in ziftomenib AML program with Kyowa Kirin. - Milestone triggered by dosing of first patient in frontline AML Phase 3 clinical program- SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced receipt of a $30 million milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura and Kyowa Kirin announced the launch of the KOMET-017 trials on September 29, 2025. KOMET-017 (NCT07007312) comprises two independent, global, randomized double-blind, placebo-controlled Phase 3 trials to evaluate ziftomenib in combination with both intensive and non-intensive chemotherapy regimens in patients with newly diagnosed NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Kura believes KOMET-017 is the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura's pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the therapeutic potential of ziftomenib and the KOMET-017 trial being the only menin inhibitor program actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact